Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and Astellas Pharma Inc. that will face a 48% discount off its 2024 list price. GSK ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

The previous price for Wegovy without insurance was $499. The cash price for popular weight-loss medications Wegovy and Ozempic is dropping by 30% in the U.S. on Monday, according to Novo Nordisk, the ...

Novo Nordisk plans "all in" launch of Wegovy pill Novo Nordisk cuts U.S. price of injectable Wegovy Price will go down to $349 per month ahead of schedule CEO Doustdar highlights consumer weight-loss ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Days after joining its fellow GLP-1 giant Eli Lilly in coming to agreements with the Trump administration to slash the costs of their uber popular weight loss meds in the U.S., Novo Nordisk has pulled ...